Clinical Trial

Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

Study acronym: BI-LIGHT
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple therapy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-03-27; most recent amendment 2025-02-03.
Trial Details
NCT Number NCT06338826
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions HIV Infections, HBV Coinfection
Enrollment 140 participants
Start Date 2025-02-01
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-05